key: cord-0937785-zx5ue0yt authors: Dehghan, Houman; Soleimani, Azam title: Pulmonary thromboembolism with multiple right heart mural thrombus in a patient with COVID-19 date: 2020-10-26 journal: J Echocardiogr DOI: 10.1007/s12574-020-00500-x sha: f48ae5b763a852693deeb02d9f5db8cc7746ca21 doc_id: 937785 cord_uid: zx5ue0yt nan Hypercoagulation state during COVID-19 disease has been confirmed recently. Herein we present a 40-year-old hypertensive otherwise healthy male who was admitted with complaints of myalgia, low grade fever, dry cough, leg swelling, and exacerbating dyspnea in the last two weeks with history of recent recovery from COVID-19 in his wife. At presentation, he was afebrile with stable vital signs (blood pressure: 114/81 mmHg, respiratory rate: 16/minute, heart rate: 75 bpm) despite hypoxemia (SPaO 2 of 74% on room air, 94% on nasal O2 therapy). Coarse crackles in the lung fields, symmetric pitting leg edema and elevated jugular venous pressure were noticed in clinical exam with low voltage QRS, extreme right axis deviation and negative T waves in the precordial leads in electrocardiogram (Fig. 1a) . Chest CT scan demonstrated pericardial and pleural effusions, filling defects in right atrium (RA) and right ventricle (RV) cavities, peripheral based ground glass opacities (compatible with COVID involvement), wedge-shaped pulmonary infarct and pulmonary arterial branch thrombosis (Fig. 1b , supplementary video1). No deep vein thrombosis was found. Transthoracic and transesophageal echocardiography showed preserved left ventricular systolic function, flattened interventricular septum, moderate right atrium (RA) and right ventricular (RV) enlargement and dysfunction, plethoric inferior vena cava with two large mural thrombi (4 cm × 2.5 cm) in RA appendage and RV apex (Fig. 1c , d, supplementary videos 2, 3). In laboratory data, positive oropharyngeal swab for severe acute respiratory syndrome corona virus 2 (SARS-COV 2 ), lymphopenia (782 per µL) without leukocytosis (4150 per µL), elevated d-dimer (4510 ng/ml, normal < 250), cardiac troponin I (115 ng/L, normal < 50) and C-reactive protein (18.9 mg/L, normal < 5) were observed. Under full intravenous anticoagulation and oral vitamin K antagonist the thrombus size was reduced significantly and RV function was improved. COVID-19 disease, has been proposed to be associated with cardiovascular manifestations including acute coronary syndrome, arrhythmia, myocarditis and thromboembolism [1] . Hypercoagulation state during COVID-19 is attributed to systemic inflammation, immobility and hypoxemia [2] . The theory of endothelial lung injury along with micro thrombus formation in pulmonary vascular bed, leads to the general agreement for anticoagulant therapy in critically ill hospitalized patients with COVID-19 as a standard prophylactic approach [3] . Although there are reports of successful thrombolytic therapy in unstableCOVID-19 patients with right heart thrombus, the stable subacute presentation of the patient, leads us to follow conservative approach [4, 5] . This patient presented with pulmonary thromboembolism accompanied by multiple large right heart thrombus represents a unique serious form of cardiopulmonary injury during COVID-19 disease. The online version of this article (https ://doi.org/10.1007/s1257 4-020-00500 -x) contains supplementary material, which is available to authorized users. Description and proposed management of the acute COVID-19 cardiovascular syndrome The European society for cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic Prevention, diagnosis, and treatment of vte in patients with coronavirus disease 2019: CHEST guideline and expert panel report Right ventricular clot in transit in COVID-19 Implications for the pulmonary embolism response team COVID19: a case report of thrombus in transit Conflict of interest Houman Dehghan and Azam Soleimani declare that they have no conflict of interest.Human rights statements and informed consent All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from the patient for being included in the study.